The Defense Threat Reduction Agency awarded a $23.1 million definitive contract to Primmune Therapeutics, Inc. for development of an oral broad spectrum antiviral TLR7 agonist for treatment of Lassa fever on January 30, 2024, under a cost-plus-fixed-fee pricing structure with no set-aside.
Place of performance is Carlsbad, California. The originating solicitation, a Broad Agency Announcement posted November 2, 2016, solicited innovative research and development projects focused on countering weapons of mass destruction across six technology areas at Technology Readiness Levels 2 through 6, accepting submissions on a rolling basis through October 2021. Work is scheduled for completion by December 31, 2027.